Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

57
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
57
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
1.5K
Tumor Progression02:07

Tumor Progression

3.1K
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroimmune pathways linking sleep disturbance to persistent pain after injury are mitigated by exercise.

Pain·2026
Same author

Conditional Stat2 Knockout Mice as a Platform for Modeling Human Diseases.

Immuno·2026
Same author

STAT2 Promotes Tumor Growth in Colorectal Cancer Independent of Type I IFN Receptor Signaling.

Current oncology (Toronto, Ont.)·2025
Same author

Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2.

Science (New York, N.Y.)·2025
Same author

Enhanced BDNF and ROS in Mucosa of Lower Motor Neuron Lesioned Dog Bladder Following Somatic Motor Nerve Transfer.

Cells·2025
Same author

Repetitive Overuse Injury Causes Entheseal Damage and Palmar Muscle Fibrosis in Older Rats.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Apr 28, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.3K

Host STAT2/type I interferon axis controls tumor growth.

Chanyu Yue1, Jun Xu, Marc Daryl Tan Estioko

  • 1Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA.

International Journal of Cancer
|June 5, 2014
PubMed
Summary
This summary is machine-generated.

Signal transducer and activator of transcription 2 (STAT2) plays a crucial role in reducing tumor growth and enhancing antitumor immunity. STAT2 deficiency impairs T-cell responses and tumor antigen presentation, highlighting its importance in cancer immunotherapy.

Keywords:
STAT1STAT2antitumorcross-presentationdendritic cellinterferonmelanoma

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.6K
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
11:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

11.7K

Related Experiment Videos

Last Updated: Apr 28, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.3K
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.6K
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
11:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

11.7K

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Type I interferons (IFNs) exhibit anti-growth effects mediated by STAT2 in vitro.
  • Evidence for STAT2's in vivo tumor suppressor function and role in antitumor immunity is limited.

Purpose of the Study:

  • To investigate the in vivo role of STAT2 in tumor growth and antitumor immunity.
  • To determine the impact of STAT2 deficiency on type I IFN-mediated anti-tumor responses.

Main Methods:

  • Syngeneic tumor transplantation model in wild type (WT) and Stat2(-/-) mice.
  • Interferon-beta (IFN-β) treatment and assessment of tumor growth.
  • Gene expression analysis of tumor tissues.
  • Assessment of dendritic cell function and T-cell responses (CD4+ and CD8+).

Main Results:

  • Stat2(-/-) mice exhibited larger tumor volumes compared to WT mice.
  • IFN-β treatment did not induce tumor regression in Stat2(-/-) mice.
  • Tumors in Stat2(-/-) mice showed downregulated immunomodulatory genes and impaired antigen cross-presentation by dendritic cells.
  • IFN-β treatment failed to increase CD4+ and CD8+ T cells in lymph nodes of Stat2(-/-) mice, unlike in WT mice.

Conclusions:

  • STAT2 is essential for mediating the antitumor effects of type I IFNs in vivo.
  • STAT2 deficiency impairs anti-tumor immunity by affecting T-cell infiltration and dendritic cell function.
  • Further evaluation of STAT2's role is warranted in patients undergoing type I IFN-based cancer immunotherapy.